CLINICAL TRIALS PROFILE FOR LENALIDOMIDE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for Lenalidomide
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Combination | NCT00974233 ↗ | Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL | Completed | Celgene Corporation | Phase 2 | 2009-10-01 | The purpose of this research is to evaluate a new combination of chemotherapy drugs for CLL/SLL using the drugs bendamustine (an intravenous chemotherapy drug), rituximab (an intravenous medication called a monoclonal antibody), and lenalidomide (an anti-cancer pill). The purpose of this study is to see if giving the chemotherapy pill lenalidomide after treatment with bendamustine and rituximab is able to prolong the period of time before the cancer starts growing again and causing symptoms. |
| New Combination | NCT00974233 ↗ | Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL | Completed | University of Wisconsin, Madison | Phase 2 | 2009-10-01 | The purpose of this research is to evaluate a new combination of chemotherapy drugs for CLL/SLL using the drugs bendamustine (an intravenous chemotherapy drug), rituximab (an intravenous medication called a monoclonal antibody), and lenalidomide (an anti-cancer pill). The purpose of this study is to see if giving the chemotherapy pill lenalidomide after treatment with bendamustine and rituximab is able to prolong the period of time before the cancer starts growing again and causing symptoms. |
| New Combination | NCT01245673 ↗ | Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma | Completed | University of Pennsylvania | Phase 2 | 2011-05-10 | One purpose of this study is to find out if a new combination of immune system treatments (MAGE-A3 vaccine plus activated T-cells) will allow the body to build up protection ("immunity") against the myeloma cells. A second purpose is to find out how well this combination of immune system treatments is able to control the myeloma. |
| New Combination | NCT01755975 ↗ | Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma | Active, not recruiting | Biologics, Inc. | Phase 1/Phase 2 | 2012-12-01 | The treatments used to treat lymphoma and multiple myeloma sometimes do not always work well or they may only work for a short period of time. This is why new treatments are being tested. This study will test a new combination of two drugs that are already approved by the Food and Drug Administration for treatment of certain kinds of blood cancers. These drugs are romidepsin and lenalidomide. Both these drugs by themselves have been used to treat lymphoma or multiple myeloma. However, while these drugs are routinely used alone, this is the first time they will be tested together. The mechanism of action of both drugs is not well understood but both have been shown to to be effective by themselves in lymphoma and multiple myeloma. |
| New Combination | NCT01755975 ↗ | Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma | Active, not recruiting | Celgene Corporation | Phase 1/Phase 2 | 2012-12-01 | The treatments used to treat lymphoma and multiple myeloma sometimes do not always work well or they may only work for a short period of time. This is why new treatments are being tested. This study will test a new combination of two drugs that are already approved by the Food and Drug Administration for treatment of certain kinds of blood cancers. These drugs are romidepsin and lenalidomide. Both these drugs by themselves have been used to treat lymphoma or multiple myeloma. However, while these drugs are routinely used alone, this is the first time they will be tested together. The mechanism of action of both drugs is not well understood but both have been shown to to be effective by themselves in lymphoma and multiple myeloma. |
| New Combination | NCT01755975 ↗ | Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma | Active, not recruiting | Saint Francis/Mount Sinai Regional Cancer Center | Phase 1/Phase 2 | 2012-12-01 | The treatments used to treat lymphoma and multiple myeloma sometimes do not always work well or they may only work for a short period of time. This is why new treatments are being tested. This study will test a new combination of two drugs that are already approved by the Food and Drug Administration for treatment of certain kinds of blood cancers. These drugs are romidepsin and lenalidomide. Both these drugs by themselves have been used to treat lymphoma or multiple myeloma. However, while these drugs are routinely used alone, this is the first time they will be tested together. The mechanism of action of both drugs is not well understood but both have been shown to to be effective by themselves in lymphoma and multiple myeloma. |
| New Combination | NCT01755975 ↗ | Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma | Active, not recruiting | University of Nebraska | Phase 1/Phase 2 | 2012-12-01 | The treatments used to treat lymphoma and multiple myeloma sometimes do not always work well or they may only work for a short period of time. This is why new treatments are being tested. This study will test a new combination of two drugs that are already approved by the Food and Drug Administration for treatment of certain kinds of blood cancers. These drugs are romidepsin and lenalidomide. Both these drugs by themselves have been used to treat lymphoma or multiple myeloma. However, while these drugs are routinely used alone, this is the first time they will be tested together. The mechanism of action of both drugs is not well understood but both have been shown to to be effective by themselves in lymphoma and multiple myeloma. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for Lenalidomide
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00031941 ↗ | CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy | Completed | National Cancer Institute (NCI) | Phase 1 | 2002-04-01 | RATIONALE: CC-5013 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have solid tumors and/or lymphoma that did not respond to previous therapy. |
| NCT00031941 ↗ | CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy | Completed | National Institutes of Health Clinical Center (CC) | Phase 1 | 2002-04-01 | RATIONALE: CC-5013 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have solid tumors and/or lymphoma that did not respond to previous therapy. |
| NCT00036894 ↗ | CC-5013 in Treating Patients With Recurrent Glioma | Completed | National Cancer Institute (NCI) | Phase 1 | 2002-03-01 | RATIONALE: CC-5013 may stop the growth of gliomas by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have recurrent glioma. |
| NCT00046735 ↗ | Phase 1 Study OF CDC-501 in Patients With Solid Tumors | Completed | Celgene | Phase 1 | 2002-06-01 | To identify the maximum tolerated dose (MTD) and safety of CDC-501 when given in a 6-week cycle in patients with solid tumors that are refractory after standard treatment. |
| NCT00046735 ↗ | Phase 1 Study OF CDC-501 in Patients With Solid Tumors | Completed | Celgene Corporation | Phase 1 | 2002-06-01 | To identify the maximum tolerated dose (MTD) and safety of CDC-501 when given in a 6-week cycle in patients with solid tumors that are refractory after standard treatment. |
| NCT00056160 ↗ | CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma | Completed | Celgene | Phase 3 | 2003-01-01 | Randomized subjects will receive CC-5013 plus high-dose dexamethasone or placebo appearing identical to CC-5013 plus high-dose dexamethasone in 4-week cycles. Each subject will participate in a treatment phase and a follow-up phase. |
| NCT00056160 ↗ | CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma | Completed | Celgene Corporation | Phase 3 | 2003-01-01 | Randomized subjects will receive CC-5013 plus high-dose dexamethasone or placebo appearing identical to CC-5013 plus high-dose dexamethasone in 4-week cycles. Each subject will participate in a treatment phase and a follow-up phase. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Lenalidomide
Condition Name
Clinical Trial Locations for Lenalidomide
Trials by Country
Clinical Trial Progress for Lenalidomide
Clinical Trial Phase
Clinical Trial Sponsors for Lenalidomide
Sponsor Name
